Guangzhou Kingmed Diagnostics Group Co., Ltd. (603882.SS)
CNY 31.24
(-1.26%)
CNY 31.24
(-1.26%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 8.53 Billion CNY | -44.92% |
| 2022 | 15.47 Billion CNY | 29.58% |
| 2021 | 11.94 Billion CNY | 44.88% |
| 2020 | 8.24 Billion CNY | 56.45% |
| 2019 | 5.26 Billion CNY | 16.44% |
| 2018 | 4.52 Billion CNY | 19.35% |
| 2017 | 3.79 Billion CNY | 17.7% |
| 2016 | 3.22 Billion CNY | 34.83% |
| 2015 | 2.38 Billion CNY | 30.01% |
| 2014 | 1.83 Billion CNY | 35.53% |
| 2013 | 1.35 Billion CNY | 38.77% |
| 2012 | 977.2 Million CNY | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 2.03 Billion CNY | 10.82% |
| 2024 Q1 | 1.83 Billion CNY | -17.46% |
| 2024 Q3 | 1.73 Billion CNY | -14.82% |
| 2023 Q3 | 2 Billion CNY | -8.66% |
| 2023 Q4 | 2.22 Billion CNY | 11.23% |
| 2023 FY | 8.52 Billion CNY | -44.92% |
| 2023 Q1 | 2.11 Billion CNY | -35.21% |
| 2023 Q2 | 2.19 Billion CNY | 3.47% |
| 2022 Q3 | 3.89 Billion CNY | -4.08% |
| 2022 Q2 | 4.06 Billion CNY | -4.47% |
| 2022 Q1 | 4.25 Billion CNY | 27.82% |
| 2022 FY | 15.47 Billion CNY | 29.58% |
| 2022 Q4 | 3.26 Billion CNY | -16.1% |
| 2021 Q2 | 2.77 Billion CNY | 3.65% |
| 2021 FY | 11.94 Billion CNY | 44.88% |
| 2021 Q4 | 3.32 Billion CNY | 5.19% |
| 2021 Q1 | 2.67 Billion CNY | 10.86% |
| 2021 Q3 | 3.16 Billion CNY | 13.87% |
| 2020 Q1 | 1.17 Billion CNY | -13.21% |
| 2020 Q2 | 2.3 Billion CNY | 96.78% |
| 2020 FY | 8.24 Billion CNY | 56.45% |
| 2020 Q4 | 2.41 Billion CNY | 2.7% |
| 2020 Q3 | 2.35 Billion CNY | 2.12% |
| 2019 Q1 | 1.16 Billion CNY | -3.61% |
| 2019 FY | 5.26 Billion CNY | 16.44% |
| 2019 Q4 | 1.34 Billion CNY | -2.04% |
| 2019 Q3 | 1.37 Billion CNY | -0.14% |
| 2019 Q2 | 1.37 Billion CNY | 18.47% |
| 2018 Q4 | 1.2 Billion CNY | 0.41% |
| 2018 FY | 4.52 Billion CNY | 19.35% |
| 2018 Q3 | 1.2 Billion CNY | 0.56% |
| 2018 Q2 | 1.19 Billion CNY | 30.23% |
| 2018 Q1 | 918.49 Million CNY | -7.39% |
| 2017 Q1 | 801.32 Million CNY | -9.91% |
| 2017 Q3 | 1 Billion CNY | 0.36% |
| 2017 Q4 | 991.73 Million CNY | -0.94% |
| 2017 Q2 | 997.55 Million CNY | 24.49% |
| 2017 FY | 3.79 Billion CNY | 17.7% |
| 2016 Q4 | 889.45 Million CNY | 4.17% |
| 2016 Q3 | 853.8 Million CNY | 0.0% |
| 2016 FY | 3.22 Billion CNY | 34.83% |
| 2015 Q4 | 678.33 Million CNY | 0.0% |
| 2015 FY | 2.38 Billion CNY | 30.01% |
| 2014 FY | 1.83 Billion CNY | 35.53% |
| 2013 FY | 1.35 Billion CNY | 38.77% |
| 2012 FY | 977.2 Million CNY | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Shanghai Runda Medical Technology Co., Ltd. | 9.14 Billion CNY | 6.644% |
| Joinn Laboratories(China)Co.,Ltd. | 2.37 Billion CNY | -259.338% |
| WuXi AppTec Co., Ltd. | 40.04 Billion CNY | 78.674% |
| Autobio Diagnostics Co., Ltd. | 4.44 Billion CNY | -92.176% |
| Thalys Medical Technology Group Inc. | 2 Billion CNY | -325.676% |
| Chemclin Diagnostics Co., Ltd. | 445.34 Million CNY | -1817.549% |